Detalhe da pesquisa
1.
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Br J Haematol;
202(2): 284-288, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37183377
2.
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cancer;
126(15): 3438-3447, 2020 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32459375